Inovio Pharmaceuticals, Inc. (INO)Healthcare | Biotechnology | Plymouth Meeting, United States | NasdaqCM
1.16 USD
-0.02
(-1.695%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.15 -0.01 (-0.009%) ⇩ (July 13, 2026, 7:05 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:43 a.m. EDT
This is a high-risk speculative vehicle masquerading as a biotech play, driven entirely by a single upcoming regulatory decision rather than sustainable business fundamentals. The company is hemorrhaging cash, with operating cash flow of -$83 million and free cash flow of -$34 million, while posting a massive -87.68% decline in the trailing twelve months. The balance sheet is fragile, with debt-to-equity exceeding 143x and no revenue to generate sales multiples. While the analyst price targets suggest a potential rebound to $5.82, this ignores the reality that the stock has lost 98.76% of its value over the last nine years. The options chain confirms this binary nature: traders are buying cheap puts to protect against failure while hoping for a miraculous approval to drive the price to $3.00. Until the October PDUFA date resolves, the probability of survival is low, and the probability of total capital loss remains the dominant risk profile. |
| Model | MAE |
|---|---|
| MSTL_97 ✓ | 0.088930 |
| MSTL_70_97 | 0.136139 |
| AutoTheta | 0.164791 |
| MSTL | 0.180851 |
| AutoETS | 0.184960 |
| AutoARIMA | 0.189148 |
| MSTL_70 | 0.214738 |
Forecast horizon: 60 days | Selected: MSTL_97
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.144 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 143.296 |
| Market Cap | 95,436,952 |
| Forward P/E | -2.83 |
| Beta | 1.49 |
| Website | https://www.inovio.com |
As of July 11, 2026, 4:43 a.m. EDT: Speculators are positioning for a binary event with asymmetric downside protection. Call volume is heavily skewed toward out-of-the-money strikes ($2.00 and $3.00) expiring in late summer and fall, suggesting a hope for a massive spike ahead of the October PDUFA date. However, put volume is concentrated in the immediate term (July expiration), with significant open interest at the $1.00 strike, indicating a fear of a crash to the lows if the catalyst fails. The lack of long-dated call liquidity suggests the market views anything beyond a binary 'yes/no' outcome as highly improbable.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.13235295 |
| Address1 | 660 West Germantown Pike |
| Address2 | Suite 110 |
| All Time High | 2,352.0 |
| All Time Low | 1.03 |
| Ask | 1.35 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 1,715,950 |
| Average Daily Volume3 Month | 2,481,277 |
| Average Volume | 2,481,277 |
| Average Volume10Days | 1,715,950 |
| Beta | 1.485 |
| Bid | 1.01 |
| Bid Size | 1 |
| Book Value | 0.087 |
| City | Plymouth Meeting |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.16 |
| Current Ratio | 1.04 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.21 |
| Day Low | 1.144 |
| Debt To Equity | 143.296 |
| Display Name | Inovio Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,704,200 |
| Earnings Call Timestamp Start | 1,778,704,200 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -82,358,176 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.807 |
| Enterprise Value | 66,450,752 |
| Eps Current Year | -1.14 |
| Eps Forward | -0.41 |
| Eps Trailing Twelve Months | -1.58 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1976 |
| Fifty Day Average Change | -0.03760004 |
| Fifty Day Average Change Percent | -0.031396158 |
| Fifty Two Week Change Percent | -13.235294 |
| Fifty Two Week High | 2.98 |
| Fifty Two Week High Change | -1.82 |
| Fifty Two Week High Change Percent | -0.6107383 |
| Fifty Two Week Low | 1.03 |
| Fifty Two Week Low Change | 0.13 |
| Fifty Two Week Low Change Percent | 0.1262136 |
| Fifty Two Week Range | 1.03 - 2.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 913,127,400,000 |
| Float Shares | 81,883,262 |
| Forward Eps | -0.41 |
| Forward P E | -2.8292682 |
| Free Cashflow | -34,469,496 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 112 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -52,186,080 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00417 |
| Held Percent Institutions | 0.47296003 |
| Implied Shares Outstanding | 82,273,237 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.inovio.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,706,140,800 |
| Last Split Factor | 1:12 |
| Long Business Summary | Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. |
| Long Name | Inovio Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 95,436,952 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_28922 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -84,934,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 97,082,419 |
| Number Of Analyst Opinions | 4 |
| Open | 1.15 |
| Operating Cashflow | -83,346,720 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 267 440 4200 |
| Post Market Change | -0.009199977 |
| Post Market Change Percent | -0.7931015 |
| Post Market Price | 1.1508 |
| Post Market Time | 1,783,983,944 |
| Previous Close | 1.18 |
| Price Eps Current Year | -1.0175438 |
| Price Hint | 4 |
| Price To Book | 13.333333 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 0.994 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -1.69491 |
| Regular Market Day High | 1.21 |
| Regular Market Day Low | 1.144 |
| Regular Market Day Range | 1.144 - 1.21 |
| Regular Market Open | 1.15 |
| Regular Market Previous Close | 1.18 |
| Regular Market Price | 1.16 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,113,700 |
| Return On Assets | -0.76361 |
| Return On Equity | -2.9635801 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 82,273,237 |
| Shares Percent Shares Out | 0.18280001 |
| Shares Short | 15,043,165 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 16,268,843 |
| Short Name | Inovio Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2087 |
| Short Ratio | 10.16 |
| Source Interval | 15 |
| State | PA |
| Symbol | INO |
| Target High Price | 13.0 |
| Target Low Price | 1.8 |
| Target Mean Price | 5.825 |
| Target Median Price | 4.25 |
| Total Cash | 37,681,256 |
| Total Cash Per Share | 0.458 |
| Total Debt | 8,695,055 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.68965 |
| Two Hundred Day Average Change | -0.5296501 |
| Two Hundred Day Average Change Percent | -0.31346732 |
| Type Disp | Equity |
| Volume | 1,113,700 |
| Website | https://www.inovio.com |
| Zip | 19,462 |